Biolexis Therapeutics

CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLern™ AI-Driven Discovery LEHI, Utah, March 14, 2025 /PRNewswire/ -- Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of the cryo-electron microscopy (cryoEM) structure of BLX-7006, its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor, distinct from any previously known approaches. The cryoEM structural confirmation validates the predictive power of MolecuLern, Biolexis' AI-enabled drug discovery platform. MolecuLern identified BLX-7006 as a novel small molecule capable of allosterically modulating GLP-1 receptor activity. Unlike many oral small-molecule GLP-1 therapies being developed—whose compounds are almost exclusively modified analogs of existing molecules such as Pfizer's Danuglipron and Eli Lilly's Orforglipron—BLX-7006 is a brand-new chemotype with an entirely unique binding mode. "The cryoEM structural confirmation of BLX-7006 provides definitive proof that we have discovered a new way to activate the GLP-1 receptor allosterically," said Dr. Hariprasad Vankayalapati, Chief Scientific Officer of Biolexis Therapeutics. "This isn't just an incremental improvement on existing compounds—it's a new mechanism enabled by our AI-driven approach to drug discovery. With superior metabolic stability and a more efficient synthesis process, BLX-7006 represents a breakthrough in the quest for next-generation, oral GLP-1 therapies." Biolexis is actively completing the toxicology and manufacturing studies necessary to support human clinical testing of BLX-7006. With these critical studies underway, the company plans to initiate first-in-human trials in Q3 2025, marking a major step toward bringing this novel therapy to patients with obesity, type 2 diabetes, and metabolic dysfunction. Asked to provide additional details on Biolexis' AI drug discovery platform, Vankayalapati stated, "MolecuLern integrates AI-driven molecular design, wet lab validation, and proprietary structural modeling to identify innovative small molecules for challenging drug targets. The successful cryoEM validation of BLX-7006's novel binding mode underscores the ability of MolecuLern to accurately predict molecular interactions and accelerate the discovery of first-in-class therapeutics." About Biolexis Therapeutics Biolexis Therapeutics is a biopharmaceutical company pioneering the discovery and development of next-generation metabolic drugs to address chronic diseases such as obesity and type 2 diabetes. Its proprietary AI-enabled drug discovery platform, MolecuLern, drives the rapid identification of novel small-molecule therapies, delivering superior efficacy and safety profiles. With a commitment to scientific excellence and patient-centered innovation, Biolexis is redefining the future of metabolic medicine. For more information, visit biolexistx.com. SOURCE Biolexis Therapeutics Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Study Demonstrates 16.6 % at day 7 to 29 % on terminal day 28 Weight Loss and Superior Efficacy Compared to peptide-based approved or clinical stage oral Obesity Drugs in the DIO Model LEHI, Utah, Dec. 9, 2024 /PRNewswire/ -- Biolexis Therapeutics, a leading metabolic drug discovery company focused on improving the lives of patients with chronic metabolic conditions, including obesity, diabetes, and related diseases, today announced the successful completion of an expanded diet -induced obesity (DIO) trial for its candidate drug, BLX-7006. The results demonstrate significant weight loss and superior efficacy compared to leading obesity therapies, including Semaglutide and Orforglipron, providing robust support for BLX-7006's potential as a transformative treatment for obesity & diabetic indications. The newly completed study builds upon a previous DIO study in which BLX-7006 demonstrated a promising 15.6 % weight loss. In the expanded study, BLX-7006 achieved a substantial 29% weight loss, attributed to evaluating higher dosage levels. These higher doses were well tolerated, with no observed toxicity, marking an important milestone in the development of BLX-7006 for obesity management. "We are extremely encouraged by the results of our expanded DIO study, which show a significant improvement in weight loss with BLX-7006 compared to our initial study," said Dr. Hariprasad Vankayalapati, Chief Scientific Officer at Biolexis Therapeutics. "The higher dosage levels are well tolerated, have yielded a 29% weight loss, which is not only a strong indication of the potential therapeutic benefits of BLX-7006, but also underscores its safety profile, with no evidence of toxicity at these elevated doses in non-clinical animal models. Our findings place BLX-7006 in a competitive position in the obesity treatment space." In addition to the DIO study, Biolexis has completed a non-human primate study to assess BLX-7006's oral bioavailability profile. The study demonstrated high exposure levels, further validating BLX-7006's potential translation into future human clinical trials. "These results are a testament to the strength of our BLX-7006 program and the dedication of our team in developing novel metabolic therapeutics," said Keith Marmer, Chief Business Officer of Biolexis Therapeutics. "With the growing global prevalence of obesity and related metabolic disorders, there is a pressing need for more effective oral treatments over current injectables. The compelling results from both our expanded DIO study and the non-human primate study position BLX-7006 as a promising future clinical candidate to address this critical unmet need." Biolexis will present these findings and additional data at the upcoming Innovation in Obesity Therapeutics Summit in San Diego, CA, on December 11-12, 2024. Biolexis Co-founder Dr. David Bearss will present the latest data on BLX-7006's efficacy and its potential to provide a safe, effective, and oral alternative for patients struggling with obesity and related metabolic conditions. "We are excited to share these groundbreaking results with the scientific community at the Innovation in Obesity Therapeutics Summit," said Dr. Bearss. "As we continue to advance BLX-7006 through clinical development, we remain committed to improving patient outcomes and bringing innovative solutions to the market that can have a meaningful impact on the lives of those affected by chronic metabolic diseases." About Biolexis Therapeutics Biolexis Therapeutics is a biopharmaceutical company focused on discovering and developing innovative metabolic drugs to address chronic diseases such as obesity, diabetes, and related conditions. The company's pipeline includes novel small-molecule oral therapies designed to improve patient outcomes with enhanced efficacy and safety profiles. Biolexis is committed to advancing the treatment of chronic metabolic disorders to enhance patients' lives worldwide. For more information about Biolexis Therapeutics and its pioneering research, please visit biolexistx.com. Forward-Looking Statements This press release contains forward-looking statements regarding the clinical development of BLX-7006, including its potential safety, efficacy, and market positioning. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially from those anticipated due to various factors, including clinical trial results, regulatory approval, and market conditions. SOURCE Biolexis Therapeutics Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DUBLIN--( BUSINESS WIRE )--The "Digital Transformation and Emerging Technologies in the Healthcare Industry 2024 Edition" report has been added to ResearchAndMarkets.com's offering. The report examines the progress of digital transformation in the pharmaceutical industry. It assesses the industry's preparedness to embrace innovation, explores the challenges and opportunities associated with digital transformation as well as highlights current and emerging trends in technology-related investments. The pharmaceutical industry is facing ongoing shifts driven by declining profit margins, increasing cost pressures, and the need to both replenish pipelines and maximize peak sales, all while adhering to strict regulatory and legislative requirements. Although adopting innovative technologies is seen as a key strategy to mitigate these challenges, the digitalization process is complex, time-consuming, and requires significant investment, along with sustained commitment and transparent dialogue with various stakeholders, including employees, investors, and regulators. The pharmaceutical industry is experiencing steady advancement in digital transformation. Mirroring 2023 survey findings, operations enablement and innovation was selected as the main scope of digital transformation in 2024. Optimism regarding the growth of digital transformation in their organizations reached record highs among the pharma industry professionals. In line with previous years' results, lack of specific skills and talents was selected as the top hinderance for digital transformation. Digital privacy and data security issues have ranked as the top concern associated with digital transformation, closely followed by cybersecurity concerns. Strong leadership was regarded as the key driver for a successful digital transformation. Pharma industry professionals are prioritizing artificial intelligence (AI) for current and future investments. Digital transformation is a must for maintaining competitive advantage in the pharmaceutical industry. Scope Benchmark the level of business readiness and technology adoption. Gain a deeper understanding of the business functions affected the most by digital transformation. Identify and assess barriers to adopting emerging technologies. Define the critical requirements for success. Determine the importance of emerging technologies to the pharmaceutical industry. Evaluate current levels of investment and identity both present and future investment priorities. Analyze the impact of COVID-19, inflation, and other factors on digitalization efforts. Explore the impact of emerging technologies on the pharmaceutical value chain. Assess the role of digital transformation in sustaining competitive advantage. Reasons to Buy Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have in the near future. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector. Develop business strategies by understanding the key factors of digital transformation and emerging technology in the healthcare sector. Identify emerging industry trends in the uptake of emerging technologies to gain a competitive advantage. Key Topics Covered: Study Design Key Findings Overview of Digital Transformation Digital Transformation Strategies Digital Transformation Objectives Obstacles to Digital Transformation Concerns Associated with Digital Transformation Necessities for Digital Transformation Emerging Technologies - Investment Trends Artificial Intelligence Case Studies Summary of Key Findings Appendix Competitive Landscape Amgen AB BenevolentAI Ltd Biolexis Therapeutics Inc Cellix Biosciences Inc Eli Lilly and Co Generate Biomedicines Inc Google Cloud Platform Hackensack Meridian Health Inc Healx Ltd Highmark Health InSilico Medicine Mount Sinai Health System Novartis AG Recursion Pharmaceuticals Inc For more information about this report visit https://www.researchandmarkets.com/r/r3umsv About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.